NCT03369353
Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial)
Enrolling by Invitation
Not specifiedAll AgesObservationalBoston Children's HospitalInvestigator-initiated
~1,000 participants
Updated 2026-03-18 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Perform flow cytometry, TCR deep sequencing and whole transcriptome analysis on T cells purified from GI endoscopy samples taken for presumed GI GVHD, inflammatory bowel disease (IBD), and functional gastrointestinal disease (FGID).
Measured over 1 year
+1 more outcome measured
Conditions
Where it's being run
4 sites across 2 statesMassachusetts3
Washington1
Study leadership
- Leslie Kean, MD, PhD · PRINCIPAL_INVESTIGATOR · Boston Children's Hospital
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Perform flow cytometry, TCR deep sequencing and whole transcriptome analysis on T cells purified from GI endoscopy samples taken for presumed GI GVHD, inflammatory bowel disease (IBD), and functional gastrointestinal disease (FGID).1 year
To identify the mechanisms specific for auto-immune and allo-immune GI disorders.
- Perform flow cytometry, TCR deep sequencing and transcriptome analysis on T cells from the peripheral blood in patients diagnosed with GI GVHD, IBD and FGID and patients receiving cellular therapies.1 year
To identify the mechanisms specific for allo- and auto-immune diseases and the consequences of cellular therapy delivery.